Vitalhub (TSE:VHI) Stock Rating Upgraded by Raymond James

Raymond James upgraded shares of Vitalhub (TSE:VHI) to a moderate buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Scotiabank set a C$14.00 price target on Vitalhub and gave the company an “outperform” rating in a research note on Thursday, January 30th. Canaccord Genuity Group lifted their target price on Vitalhub from C$12.00 to C$12.50 and gave the company a “buy” rating in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of C$11.92.

Vitalhub Price Performance

Shares of TSE:VHI opened at C$9.66 on Wednesday. Vitalhub has a 1 year low of C$5.80 and a 1 year high of C$12.09. The stock has a market capitalization of C$522.53 million, a price-to-earnings ratio of 157.12, a price-to-earnings-growth ratio of 1.18 and a beta of 1.26. The company’s 50 day simple moving average is C$10.49 and its 200 day simple moving average is C$10.31.

Vitalhub Company Profile

Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.